School of Medicine Greenville, University of South Carolina, Greenville, South Carolina, USA.
School of Medicine, Oregon Health and Science University, Portland, Oregon, USA.
Cancer Rep (Hoboken). 2023 Dec;6(12):e1908. doi: 10.1002/cnr2.1908. Epub 2023 Oct 11.
Little is known regarding anal cancer patients' perspectives on undergoing radiation therapy. Additionally, the stigma surrounding anal cancer diagnosis warrants a better understanding of the barriers to complete disclosure in patient-healthcare team interactions.
Included patients had squamous cell carcinoma of the anus treated with definitive chemoradiation (CRT) from 2009 to 2018. Survey questions were adapted from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and Discrimination and Stigma Scale.
A total of 46 anal cancer patients who underwent CRT were surveyed, of which 72% responded. 73% of respondents indicated little to no pre-treatment knowledge of CRT. 70% reported overall short-term effects as worse than expected, most commonly with bowel habits (82%), energy (73%), and interest in sexual activity (64%). 39% reported overall long-term effects to be worse than expected, most commonly with changes to bowel habits (73%), sexual function (67%), and interest in sexual activity (58%). However, 94% agreed they were better off after treatment. Regarding stigma, a subset reported hiding their diagnosis (12%, 24%) and side effects (24%, 30%) from friends/family or work colleagues, respectively, and 15% indicating they stopped having close relationships due to concerns over stigma.
Although patients' perceptions of the severity of short-term CRT side effects were worse than expectations, the vast majority agreed they were better off after treatment. Targeted counseling on common concerns may improve the anal cancer treatment experience. A notable subset reported stigma associated with treatment, warranting further evaluation to understand the impact on the patient experience.
对于接受放射治疗的肛门癌患者的观点,我们知之甚少。此外,肛门癌诊断所带来的耻辱感要求我们更好地了解患者与医疗团队互动中完全披露的障碍。
纳入的患者患有 2009 年至 2018 年期间接受根治性放化疗(CRT)治疗的肛门鳞状细胞癌。调查问题改编自欧洲癌症研究和治疗组织生活质量问卷和歧视与耻辱量表。
共有 46 名接受 CRT 的肛门癌患者接受了调查,其中 72%的患者做出了回应。73%的受访者表示,在 CRT 治疗前对其知之甚少。70%的人报告短期总体效果比预期差,最常见的是肠道习惯(82%)、能量(73%)和对性活动的兴趣(64%)。39%的人报告长期总体效果比预期差,最常见的是肠道习惯改变(73%)、性功能(67%)和对性活动的兴趣(58%)。然而,94%的人表示治疗后他们的情况更好。关于耻辱感,有一部分人报告分别向朋友/家人或工作同事隐瞒了自己的诊断(12%,24%)和副作用(24%,30%),15%的人表示由于担心耻辱感,他们停止了亲密关系。
尽管患者对 CRT 短期副作用严重程度的认知比预期更差,但绝大多数患者表示治疗后情况更好。针对常见问题进行有针对性的咨询可能会改善肛门癌的治疗体验。有相当一部分人报告了与治疗相关的耻辱感,这需要进一步评估以了解其对患者体验的影响。